- Home
- PASG vs RADX Comparison
PASG vs RADX Comparison
Compare PASG & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- RADX
- Stock Information
- Founded
- PASG 2017
- RADX 2021
- Country
- PASG United States
- RADX Australia
- Employees
- PASG N/A
- RADX N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- PASG Health Care
- RADX
- Exchange
- PASG Nasdaq
- RADX NYSE
- Market Cap
- PASG 31.1M
- RADX 31.8M
- IPO Year
- PASG 2020
- RADX N/A
- Fundamental
- Price
- PASG $0.37
- RADX $4.12
- Analyst Decision
- PASG Strong Buy
- RADX Strong Buy
- Analyst Count
- PASG 3
- RADX 2
- Target Price
- PASG $7.67
- RADX $13.50
- AVG Volume (30 Days)
- PASG 193.4K
- RADX 29.1K
- Earning Date
- PASG 05-20-2025
- RADX 02-26-2025
- Dividend Yield
- PASG N/A
- RADX N/A
- EPS Growth
- PASG N/A
- RADX N/A
- EPS
- PASG N/A
- RADX N/A
- Revenue
- PASG N/A
- RADX $204,609.00
- Revenue This Year
- PASG N/A
- RADX N/A
- Revenue Next Year
- PASG N/A
- RADX N/A
- P/E Ratio
- PASG N/A
- RADX N/A
- Revenue Growth
- PASG N/A
- RADX N/A
- 52 Week Low
- PASG $0.30
- RADX $3.50
- 52 Week High
- PASG $1.64
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- PASG 46.97
- RADX N/A
- Support Level
- PASG $0.33
- RADX N/A
- Resistance Level
- PASG $0.42
- RADX N/A
- Average True Range (ATR)
- PASG 0.04
- RADX 0.00
- MACD
- PASG 0.01
- RADX 0.00
- Stochastic Oscillator
- PASG 33.27
- RADX 0.00
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.